# Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis

> **NCT05057052** · PHASE2 · RECRUITING · sponsor: **Fudan University** · enrollment: 25 (estimated)

## Conditions studied

- Liver Metastases
- Colorectal Cancer Metastatic

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Regorafenib
- **COMBINATION_PRODUCT:** US/CT-guided Percutaneous Cryoablation

## Key facts

- **NCT ID:** NCT05057052
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-09-26
- **Primary completion:** 2026-09-25
- **Final completion:** 2026-09-25
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05057052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05057052, "Cryoablation Combined with Sintilimab Plus Regorafenib in Previously Treated Colorectal Cancer Liver Metastasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05057052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*